Joseph Mikhael1,2, Nofisat Ismaila3, Matthew C Cheung4, Caitlin Costello5, Madhav V Dhodapkar6, Shaji Kumar7, Martha Lacy7, Brea Lipe8, Richard F Little9, Anna Nikonova10, James Omel11, Namrata Peswani12, Anca Prica13, Noopur Raje14, Rahul Seth15, David H Vesole16,17, Irwin Walker18, Alexander Whitley19, Tanya M Wildes20, Sandy W Wong21, Tom Martin21. 1. 1 City of Hope Cancer Center, Phoenix, AZ. 2. 2 International Myeloma Foundation, North Hollywood, CA. 3. 3 American Society of Clinical Oncology, Alexandria VA. 4. 4 Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 5. 5 UC San Diego Moores Cancer Center, La Jolla, CA. 6. 6 Emory University, Atlanta, GA. 7. 7 Mayo Clinic, Rochester MN. 8. 8 University of Rochester Medical Center, Rochester, NY. 9. 9 National Cancer Institute, Bethesda, MD. 10. 10 Juravinski Cancer Center, Hamilton, Ontario, Canada. 11. 11 Education and Advocacy, Grand Island, NE. 12. 12 Advocate Medical Group, Chicago, IL. 13. 13 Princess Margaret Cancer Centre, Toronto, Ontario, Canada. 14. 14 Massachusetts General Hospital, Boston, MA. 15. 15 Upstate Medical University, Syracuse, NY. 16. 16 Hackensack University Medical Center, Hackensack, NJ. 17. 17 Georgetown University, Washington, DC. 18. 18 McMaster University, Hamilton, Ontario, Canada. 19. 19 Central Alabama Radiation Oncology, Montgomery, AL. 20. 20 Washington University Medical School, St Louis, MO. 21. 21 University of California San Francisco, San Francisco, CA.
Abstract
PURPOSE: To provide evidence-based recommendations on the treatment of multiple myeloma to practicing physicians and others. METHODS: ASCO and Cancer Care Ontario convened an Expert Panel of medical oncology, surgery, radiation oncology, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and some phase II studies published from 2005 through 2018. Outcomes of interest included survival, progression-free survival, response rate, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 124 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations were developed for patients with multiple myeloma who are transplantation eligible and those who are ineligible and for patients with relapsed or refractory disease.
PURPOSE: To provide evidence-based recommendations on the treatment of multiple myeloma to practicing physicians and others. METHODS: ASCO and Cancer Care Ontario convened an Expert Panel of medical oncology, surgery, radiation oncology, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and some phase II studies published from 2005 through 2018. Outcomes of interest included survival, progression-free survival, response rate, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 124 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations were developed for patients with multiple myeloma who are transplantation eligible and those who are ineligible and for patients with relapsed or refractory disease.
Authors: Peter M Voorhees; Jonathan L Kaufman; Jacob Laubach; Douglas W Sborov; Brandi Reeves; Cesar Rodriguez; Ajai Chari; Rebecca Silbermann; Luciano J Costa; Larry D Anderson; Nitya Nathwani; Nina Shah; Yvonne A Efebera; Sarah A Holstein; Caitlin Costello; Andrzej Jakubowiak; Tanya M Wildes; Robert Z Orlowski; Kenneth H Shain; Andrew J Cowan; Sean Murphy; Yana Lutska; Huiling Pei; Jon Ukropec; Jessica Vermeulen; Carla de Boer; Daniela Hoehn; Thomas S Lin; Paul G Richardson Journal: Blood Date: 2020-08-20 Impact factor: 22.113
Authors: Susan Bal; Heather J Landau; Gunjan L Shah; Michael Scordo; Parastoo Dahi; Oscar B Lahoud; Hani Hassoun; Malin Hultcrantz; Neha Korde; Nikoletta Lendvai; Alexander M Lesokhin; Sham Mailankody; Urvi A Shah; Eric Smith; Sean M Devlin; Scott Avecilla; Ahmet Dogan; Mikhail Roshal; Ola Landgren; Sergio A Giralt; David J Chung Journal: Biol Blood Marrow Transplant Date: 2020-05-19 Impact factor: 5.742
Authors: Megan M Dupuis; Barry Paul; Gavin Loitsch; Parker Mathews; Daniel Feinberg; Ian Barak; Zhiguo Li; Sascha A Tuchman; Yubin Kang Journal: JCO Oncol Pract Date: 2020-04-02